Early Identification and Effective Management of Pediatric Sepsis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

175 participants

Study Classification

OBSERVATIONAL

Study Start Date

2018-10-01

Study Completion Date

2021-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In patients diagnosed as sepsis on PICU admission, early and accurate identification of patients who will develop organ dysfunction (severe sepsis) is critical for effective management and positive outcome. A multiple marker approach would improve clinical utility compared with use of a single marker. The primary goal of this part of study is to define a combination of multiple markers, derived from novel biomarkers (nCD-64, IL-27, sTREM, HLA-DR, IL-10), metabolomics and routine clinical parameters, which could predict severe sepsis and determine the severity of disease.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Impact of Sepsis on Long-term Outcomes in Critical Ill Children With Sepsis

NCT06323226

Sepsis Children, Only

RECRUITING

Study on the Efficacy and Timing of ECMO Therapy in Children With Refractory Septic Shock

NCT03948048

Septic Shock Extracorporeal Membrane Oxygenation Complication

RECRUITING

Novel Biomarkers for Early Renal Injury in Children With Sepsis

NCT06197828

Acute Kidney Injury Sepsis Gout Flare

ACTIVE_NOT_RECRUITING

Electronic Application of a Severe Sepsis Screening Tool and Management Bundle

NCT01724463

Systemic Inflammatory Response Syndrome (SIRS) Sepsis Severe Sepsis +1 more

UNKNOWN

Treatment of IL-6 and Its Receptor Antagonists in Children's Severe Sepsis.

NCT04850443

Critical Illness Sepsis, Severe

WITHDRAWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

We intend to enroll pediatric sepsis patients at four PICUs and divide them into two groups based on clinical outcomes: severe sepsis group (patients who progress into severe sepsis), sepsis group (patients who do not progress in to severe sepsis). We intend to perform predictive modeling using multivariable analyses of the novel biomarkers and derive a biomarker panel and algorithm for early diagnosis of severe sepsis. The predictive value of the biomarker panel for early identification of severe sepsis will be compared with established indices, such as PRISM III and pSOFA score.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Severe Sepsis Sepsis Septic Shock

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

severe sepsis

patients who diagnosed as sepsis upon PICU admission and develop organ dysfunction during PICU stay

No interventions assigned to this group

sepsis

patients recover from sepsis without developing into organ dysfunction

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* The presence of at least two of the following four criteria, one of which must be abnormal temperature or leukocyte count:

* Coreb temperature of \>38.5°C or \<36°C.
* Tachycardia, defined as a mean heart rate \>2 SD above normal for age in the absence of external stimulus, chronic drugs, or painful stimuli; or otherwise unexplained persistent elevation over a 0.5- to 4-hr time period OR for children \<1 yr old: bradycardia, defined as a mean heart rate \<10th percentile for age in the absence of external vagal stimulus, β-blocker drugs, or congenital heart disease; or otherwise unexplained persistent depression over a 0.5-hr time period.
* Mean respiratory rate \>2 SD above normal for age or mechanical ventilation for an acute process not related to underlying neuromuscular disease or the receipt of general anesthesia.
* Leukocyte count elevated or depressed for age (not secondary to chemotherapy-induced leukopenia) or \>10% immature neutrophils
* A suspected or proven (by positive culture, tissue stain, or polymerase chain reaction test) infection caused by any pathogen OR a clinical syndrome associated with a high probability of infection. Evidence of infection includes positive findings on clinical exam, imaging, or laboratory tests